Diligence memo · auto-generated · as of July 2, 2026
MI:RNA Ltd
MI:RNA Ltd looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
MI:RNA Ltd operates in Biotechnology, based in EDINBURGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
MI:RNA Ltd has raised $4.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.4M on 2024-06-28.
Most recent recorded round closed around 2024-06-28.
Valuation (modeled)modeled
Provath models MI:RNA Ltd at approximately $23M (range $4.8M–$51M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.53× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 15.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 42% of Biotechnology peers (4293 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.